COVID-19 Acute Respiratory Distress Syndrome
Conditions
Keywords
ARDS, respiratory failure, COVID-19
Brief summary
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Detailed description
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Interventions
OTHERoutcome
hospital survivors and nonsurvivors
OTHERSubtype of COVID-19
Different subtype of COVID-19
Sponsors
Southeast University, China
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest)；
Exclusion criteria
* Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of Transcutaneous partial pressure of oxygen | up to 30 days | Level of Transcutaneous partial pressure of oxygen |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of Transcutaneous partial pressure of oxygen/FiO2 | up to 30 days | Level of Transcutaneous partial pressure of oxygen/FiO2 |
Countries
China
Contacts
Primary ContactJingyuan Xu, M.D.
Outcome results
None listed